Sensorion SA Asset Resilience Ratio

Latest as of December 2025: 92.55%

Sensorion SA asset resilience ratio. Sensorion SA (ALSEN) has an Asset Resilience Ratio of 92.55% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Sensorion SA (ALSEN) defensive interval to measure how many days the company can operate on defensive assets alone.

Liquid Assets

€53.57 Million
≈ $62.63 Million USD Cash + Short-term Investments

Total Assets

€57.89 Million
≈ $67.68 Million USD All company assets

Resilience Assessment

Very High
Financial Resilience Level

Asset Resilience Ratio of Sensorion SA (2016–2025)

Asset resilience ratio of Sensorion SA from 2016 to 2025. This chart shows how Sensorion SA's Asset Resilience Ratio has changed over time. Read Sensorion SA total liabilities for a breakdown of total debt and financial obligations.

Liquid Assets Composition Over Time

This chart breaks down Sensorion SA's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see ALSEN total assets.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents €26.79 Million 46.27%
Short-term Investments €26.79 Million 46.27%
Total Liquid Assets €53.57 Million 92.55%

Asset Resilience Insights

  • Very High Liquidity: Sensorion SA maintains exceptional liquid asset reserves at 92.55% of total assets.
  • This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
  • The company maintains a balanced mix of cash and short-term investments.

Sensorion SA Industry Peers by Asset Resilience Ratio

Compare Sensorion SA's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
Biotechnology 0.00%
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578
Biotechnology 21.11%
Xiamen Amoytop Biotech Co Ltd
SHG:688278
Biotechnology 4.69%
Neuren Pharmaceuticals Ltd
AU:NEU
Biotechnology 90.43%
Chengdu Easton Biopharmaceuticals Co Ltd
SHG:688513
Biotechnology 35.16%
China Resources Boya Bio pharmaceutical Group Co Ltd
SHE:300294
Biotechnology 23.15%
Wuhan Keqian Biology Co Ltd
SHG:688526
Biotechnology 19.42%
Achieve Life Sciences Inc
F:SP4P
Biotechnology 3.60%

Sensorion SA Asset Resilience Ratio by Year (2016–2025)

Sensorion SA asset resilience ratio by year from 2016 to 2025. The table below shows the annual Asset Resilience Ratio data for Sensorion SA.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2025-12-31 92.55% €53.57 Million
≈ $62.63 Million
€57.89 Million
≈ $67.68 Million
+22.91pp
2024-12-31 69.64% €62.18 Million
≈ $72.69 Million
€89.28 Million
≈ $104.37 Million
+34.24pp
2020-12-31 35.41% €24.03 Million
≈ $28.09 Million
€67.87 Million
≈ $79.35 Million
+9.15pp
2019-12-31 26.25% €10.00 Million
≈ $11.69 Million
€38.09 Million
≈ $44.53 Million
+26.08pp
2018-12-31 0.17% €16.00K
≈ $18.71K
€9.47 Million
≈ $11.07 Million
-85.87pp
2017-12-31 86.04% €9.60 Million
≈ $11.23 Million
€11.16 Million
≈ $13.05 Million
+14.10pp
2016-12-31 71.94% €8.53 Million
≈ $9.97 Million
€11.85 Million
≈ $13.86 Million
--
pp = percentage points

About Sensorion SA

PA:ALSEN France Biotechnology
Market Cap
$5.52 Billion
€4.72 Billion EUR
Market Cap Rank
#18264 Global
#266 in France
Share Price
€9.16
Change (1 day)
+6.03%
52-Week Range
€0.22 - €10.47
All Time High
€12.53
About

Sensorion SA, a biotechnology company, engages in the development of novel therapies to restore, treat, and prevent hearing loss disorders in France. The company develops SENS-501, a dual AAV vector gene therapy development product for restoring hearing in patients with mutations in OTOF gene in Phase 1/2 clinical trials; and SENS-601, a candidate for the treatment of hearing loss caused by mutat… Read more